Cargando…
A Changing Landscape in Castration-Resistant Prostate Cancer Treatment
Prostate cancer (PC) is the leading cause of cancer and the second leading cause of cancer-death among men in the Western world. About 10–20% of men with PC present with metastatic disease at diagnosis, while 20–30% of patients diagnosed with localized disease will eventually develop metastases. Alt...
Autores principales: | Felici, A., Pino, M. S., Carlini, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399094/ https://www.ncbi.nlm.nih.gov/pubmed/22826702 http://dx.doi.org/10.3389/fendo.2012.00085 |
Ejemplares similares
-
Emerging Targeted Therapies for Castration-Resistant Prostate Cancer
por: Adamo, Vincenzo, et al.
Publicado: (2012) -
CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine
por: Chen, Xi, et al.
Publicado: (2022) -
The changing landscape of hormonal therapy in castration-resistant prostate cancer
por: Dongre, Amol, et al.
Publicado: (2012) -
Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer
por: Harris, Anna E., et al.
Publicado: (2022) -
The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer
por: Grasso, Catherine S., et al.
Publicado: (2012)